CD4 and myeloid sarcoma: Studies on the cytotoxic behavior of CD3+CD20+ T cells in progressive MS revealed an increase in CD4+ T cells in the peripheral blood of RRMS patients, as reflected by the ectopic expression of serine-protease granzyme [41]; this effect was particularly evident during natalizumab therapy.